Preclinical and first‐in‐human phase I studies of
            KW
            ‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Insulin Like Growth Factor ◽

Phase I Studies ◽

Receptor Selectivity

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

10.1200/jco.2010.28.15_suppl.3016 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3016-3016 ◽

Cited By ~ 6

Author(s):

V. M. Macaulay ◽

M. R. Middleton ◽

S. G. Eckhardt ◽

R. A. Juergens ◽

A. W. Stephens ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Insulin Receptor ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor

Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.

10.1200/jco.2010.28.15_suppl.2530 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2530-2530 ◽

Cited By ~ 10

Author(s):

C. P. Carden ◽

E. S. Kim ◽

R. L. Jones ◽

S. M. Alam ◽

F. M. Johnson ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Insulin Receptor ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

10.1200/jco.2011.29.15_suppl.3098 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3098-3098 ◽

Cited By ~ 3

Author(s):

V. M. Macaulay ◽

M. R. Middleton ◽

S. G. Eckhardt ◽

R. A. Juergens ◽

C. M. Rudin ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Insulin Receptor ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor

Phase I and pharmacokinetic (PK) Study of CP-724,714, an oral human epidermal growth factor receptor-2 (HER-2) selective tyrosine kinase inhibitor

10.1200/jco.2004.22.14_suppl.3082 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3082-3082

Author(s):

P. N. Munster ◽

M. Mita ◽

C. Britten ◽

S. Minton ◽

S. Moulder ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Her 2 ◽

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Neuro-Oncology ◽

10.1093/neuonc/now185 ◽

2016 ◽

pp. now185 ◽

Cited By ~ 2

Author(s):

Tracy T. Batchelor ◽

Elizabeth R. Gerstner ◽

Xiaobu Ye ◽

Serena Desideri ◽

Daniel G. Duda ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Phase Ii ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Recurrent Glioblastoma ◽

Platelet Derived Growth Factor ◽

Phase Ii Studies

Phase I and pharmacokinetic (PK) Study of CP-724,714, an oral human epidermal growth factor receptor-2 (HER-2) selective tyrosine kinase inhibitor

10.1200/jco.2004.22.90140.3082 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3082-3082

Author(s):

P. N. Munster ◽

M. Mita ◽

C. Britten ◽

S. Minton ◽

S. Moulder ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Her 2 ◽

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

10.1200/jco.2010.28.15_suppl.2531 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2531-2531 ◽

Cited By ~ 6

Author(s):

T. Evans ◽

C. R. Lindsay ◽

E. Chan ◽

B. Tait ◽

S. A. Michael ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Insulin Receptor ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

10.32388/jfobd7 ◽

2020 ◽

Author(s):

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Association between E-cadherin and sensitivity of hepatocellular carcinoma to treatment with epidermal growth factor receptor tyrosine kinase inhibitor

Academic Journal of Second Military Medical University ◽

10.3724/sp.j.1008.2014.00915 ◽

2014 ◽

Vol 35 (8) ◽

pp. 915

Author(s):

Rong-chun XING ◽

Jun ZHENG ◽

Ping CHEN ◽

Wei-hong ZHENG ◽

Wei LIU ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-021-03731-2 ◽

2021 ◽

Author(s):

Yu-Jin Wang ◽

Qing-Wen Wang ◽

Dong-Hu Yu ◽

Cong-Kuan Song ◽

Zi-Xin Guo ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽